AMPC, asian mouse phenotyping consortium; AP, anchor pharmacophore; AR, aromatic ring; AUC, area under the curve; Anchor pharmacophore; BACE1, beta-secretase 1; BRD4, bromodomain-containing protein 4; CA, carbonic anhydrase; CA2, carbonic anhydrase 2; CDK2, cyclin-dependent kinase 2; CTS, cathepsins; CV, covalent bonding; CatK, cathepsin K; EF, enrichment factor; EX, exclusion volume; GA, genetic algorithm; HA, hydrogen-bond acceptor; HD, hydrogen-bond donor; HIV-P, human immunodeficiency virus protease; HIV1-P, human immunodeficiency virus type 1 protease; HY, hydrophobic; IDO1, indoleamine 2,3-dioxygenase 1; IMP, imipenemase; Indoleamine 2,3-dioxygenase; LE, ligand efficiency; MAPK14, mitogen-activated protein kinase 14; MB, metal coordination; MBL, metallo-ß-lactamase; MIC, minimum inhibitory concentration; MMP, matrix metalloproteinase; MMP13, matrix metallopeptidase 13; Metallo-ß-lactamase; Metalloenzyme; NDM, new delhi MBL; NE, negatively charged center; NP, without anchor pharmacophore features; PO, positively charged center; RMSD, root mean square deviation; ROC curve, receiver operating characteristic curve; ROCK1, rho-associated protein kinase 1; RT, reverse transcriptase; RTK, receptor tyrosine kinase; SBL, serine beta lactamase; SSEL, secondary structure element length; STK, serine threonine kinase; TDO, tryptophan 2,3-dioxygenase; TDSS, torsion-driving systematic search; TNKS2, tankyrase 2; Tryptophan 2,3-dioxygenase; VEGFR2, vascular endothelial growth factor receptor 2; VIM, verona integron-encoded MBL; Virtual screening